Over the next ten years, PBMs and specialty pharmacies will save payers and patients an estimated total of $250 billion on the cost of specialty medications and related non-drug medical costs when compared to what expenditures would be with limited use of PBMs and specialty pharmacies.
Learn MoreDrug Coupons & Assistance Programs
Fraud, Waste & Abuse
Value & Outcome-Based Contracting
Drug Coverage Mandates
Pharmacy Contracting & Reimbursement
Drug Abuse Prevention
PCMA hosts three annual events: the sPCMA Business Forum, the PBM Policy Forum, and the PCMA Annual Meeting
PCMA’s conference brand is known for bringing together thought leaders and pharmacy benefit decision makers from PBMs, specialty pharmacies, and pharma and biotech manufacturers.
Learn MorePBMs Provide the HELP Committee with Policy Solutions to Increase Competition, Reduce Rx Costs
June 13, 2017
(Washington, D.C.)— As the Senate Committee on Health, Education, Labor and Pensions (HELP) examines the drug delivery system, the Pharmaceutical Care...
PCMA: Supreme Court Ruling on Biosimilars to Increase Competition, Reduce Drug Costs
June 12, 2017
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement regarding today’s ruling by the United States...
PCMA Report: Drugmakers Raise Prices Regardless of Rebates
June 12, 2017
(Washington, D.C.) — As the Senate Committee on Health, Education, Labor and Pensions examines the drug delivery system during...
PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others. PBMs are projected to save employers, unions, government programs, and consumers $654 billion— up to 30 percent—on drug benefit costs over the next decade.